|
Valoración de DCF de Karyopharm Therapeutics Inc. (KPTI)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Karyopharm Therapeutics Inc. (KPTI) Bundle
¡Optimice su eficiencia y mejore la precisión con nuestra calculadora DCF (KPTI)! Utilizando datos reales de Charyopharm Therapeutics Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y valor (KPTI) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.9 | 108.1 | 209.8 | 157.1 | 146.0 | 205.2 | 288.2 | 404.9 | 568.9 | 799.2 |
| Revenue Growth, % | 0 | 164.31 | 94.12 | -25.14 | -7.03 | 40.49 | 40.49 | 40.49 | 40.49 | 40.49 |
| EBITDA | -182.9 | -167.9 | -97.0 | -139.3 | -118.4 | -170.7 | -239.8 | -336.9 | -473.3 | -665.0 |
| EBITDA, % | -447.34 | -155.3 | -46.22 | -88.69 | -81.09 | -83.2 | -83.2 | -83.2 | -83.2 | -83.2 |
| Depreciation | 1.0 | 1.0 | .8 | .6 | .5 | 1.8 | 2.5 | 3.6 | 5.0 | 7.1 |
| Depreciation, % | 2.38 | 0.89929 | 0.37604 | 0.39536 | 0.36293 | 0.88309 | 0.88309 | 0.88309 | 0.88309 | 0.88309 |
| EBIT | -183.9 | -168.8 | -97.8 | -139.9 | -119.0 | -171.2 | -240.5 | -337.8 | -474.6 | -666.8 |
| EBIT, % | -449.72 | -156.2 | -46.6 | -89.08 | -81.46 | -83.43 | -83.43 | -83.43 | -83.43 | -83.43 |
| Total Cash | 264.0 | 273.5 | 228.6 | 278.0 | 191.4 | 205.2 | 288.2 | 404.9 | 568.9 | 799.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.9 | 12.9 | 22.5 | 47.1 | 27.0 | 37.1 | 52.1 | 73.1 | 102.7 | 144.3 |
| Account Receivables, % | 19.23 | 11.92 | 10.72 | 29.98 | 18.46 | 18.06 | 18.06 | 18.06 | 18.06 | 18.06 |
| Inventories | .3 | 2.6 | 4.1 | 4.2 | 3.0 | 4.1 | 5.8 | 8.1 | 11.4 | 16.0 |
| Inventories, % | 0.84611 | 2.45 | 1.96 | 2.69 | 2.08 | 2 | 2 | 2 | 2 | 2 |
| Accounts Payable | 1.0 | 4.5 | 1.6 | 2.8 | 3.1 | 4.6 | 6.5 | 9.1 | 12.7 | 17.9 |
| Accounts Payable, % | 2.41 | 4.12 | 0.76399 | 1.77 | 2.14 | 2.24 | 2.24 | 2.24 | 2.24 | 2.24 |
| Capital Expenditure | -.2 | -.1 | -5.7 | -.1 | .0 | -1.4 | -2.0 | -2.8 | -3.9 | -5.5 |
| Capital Expenditure, % | -0.50375 | -0.13415 | -2.72 | -0.07512383 | 0 | -0.68708 | -0.68708 | -0.68708 | -0.68708 | -0.68708 |
| Tax Rate, % | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 |
| EBITAT | -183.9 | -169.1 | -98.0 | -140.2 | -119.2 | -171.2 | -240.5 | -337.8 | -474.6 | -666.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -190.4 | -172.1 | -116.8 | -163.3 | -97.0 | -180.4 | -254.7 | -357.8 | -502.7 | -706.3 |
| WACC, % | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,383.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -720 | |||||||||
| Terminal Value | -8,052 | |||||||||
| Present Terminal Value | -4,790 | |||||||||
| Enterprise Value | -6,174 | |||||||||
| Net Debt | 125 | |||||||||
| Equity Value | -6,298 | |||||||||
| Diluted Shares Outstanding, MM | 114 | |||||||||
| Equity Value Per Share | -55.14 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to develop various scenarios.
- Real-World Data: Karyopharm Therapeutics Inc.'s (KPTI) financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Leverages Karyopharm’s actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Remove the complexity of creating intricate valuation models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Karyopharm Therapeutics Inc. (KPTI) preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. See Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.
Why Choose Karyopharm Therapeutics Inc. (KPTI)?
- Innovative Treatments: Pioneering therapies targeting cancer and other serious diseases.
- Robust Pipeline: A diverse portfolio of drug candidates in various stages of development.
- Expert Leadership: A team of seasoned professionals with extensive industry experience.
- Commitment to Research: Ongoing investment in research and development to advance healthcare solutions.
- Strong Partnerships: Collaborations with leading organizations enhance our capabilities and reach.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing Karyopharm Therapeutics Inc. (KPTI) in their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding Karyopharm Therapeutics Inc. (KPTI).
- Consultants and Advisors: Offer clients precise valuation insights related to Karyopharm Therapeutics Inc. (KPTI) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling with Karyopharm Therapeutics Inc. (KPTI).
- Biotech Enthusiasts: Gain insights into how biotech firms like Karyopharm Therapeutics Inc. (KPTI) are valued in the financial markets.
What the Template Contains
- Preloaded KPTI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.